

visibility composition may further include additional radiopaque particles or contrast particles mixed in with the composition, which have a particle size between about 120 μ and 350 μ , preferably between about 120 μ and 250 μ .

IN THE CLAIMS

Claims 33-43 should read as follows in view of this Amendment and the Second Preliminary Amendment filed December 17, 2001:

33. An injectable composition comprising:
a biocompatible matrix;
radiopaque particles mixed within said biocompatible matrix, said radiopaque particles having a particle size between about 120 μ and 2200 μ ; and
liquid contrast agent.
34. The injectable composition of claim 33, wherein said biocompatible matrix and said radiopaque particles form a slurry.
35. The injectable composition of claim 33, wherein the mixture of said biocompatible matrix and said radiopaque particles forms a hard tissue implant material.
36. The injectable composition of claim 33, wherein said radiopaque particles have a particle size between about 350 μ and 2200 μ .
37. The injectable composition of claim 36, further comprising:
radiopaque particles for contrast having a particle size between about 120 μ and 350 μ .
38. The injectable composition of claim 36, wherein said radiopaque particles have a particle size between about 450 μ and 1600 μ .
39. The injectable composition of claim 38, wherein said radiopaque particles having a particle size between about 570 μ and 1150 μ .
40. An enhanced visibility composition comprising:
a flowable matrix; and
radiopaque particles in said flowable matrix, said radiopaque particles having a size between about 350 μ and about 2200 μ so as to be individually visible during implantation.
41. The enhanced visibility composition of claim 40, wherein said radiopaque particles have a size between about 570 μ and 2200 μ .
42. The enhanced visibility composition of claim 40, wherein said radiopaque particles have a size between about 450 μ and 1600 μ .

43. The enhanced visibility composition of claim 40, wherein said radiopaque particles have a size between about 570 μ and 1150 μ .

Please enter the following new claims, corresponding to original claims 33-41, except to the extent explained in the Remarks below

44. (New) The injectable composition of claim 40, further comprising:
radiopaque particles for contrast having a particle size between about 120 μ and 350 μ .

45. (New) The injectable composition of claim 40, further comprising:
radiopaque particles for contrast having a particle size up to about 350 μ .

46. (New) The injectable composition of claim 36, further comprising:
radiopaque particles for contrast having a particle size up to about 350 μ .

47. (New) An injectable composition comprising:
a hard tissue implant biocompatible matrix; and
radiopaque particles mixed within said biocompatible matrix, said radiopaque particles having a particle size between about 120 μ and 2200 μ .

48. (New) The injectable composition of claim 47, wherein said biocompatible matrix and said radiopaque particles form a slurry.

49. (New) The injectable composition of claim 47, wherein said radiopaque particles have a particle size between about 350 μ and 2200 μ .

50. (New) The injectable composition of claim 47, wherein said radiopaque particles have a particle size between about 450 μ and 1600 μ .

51. (New) The injectable composition of claim 50, wherein said radiopaque particles have a particle size between about 570 μ and 1150 μ .

52. (New) The injectable composition of claim 49, further comprising:
radiopaque particles for contrast having a particle size between about 120 μ and 350 μ .

53. (New) The injectable composition of claim 49, further comprising:
radiopaque particles for contrast having a particle size up to about 350 μ .

REMARKS

Formal Matters

Claims 33-53 are pending after entry of the amendments set forth herein.

Claims 33-41 were examined in the Office Action dated December 19,2001 prior to entry of the Second Preliminary Amendment filed by Applicant on December 4, 2001. As such, claims 33-41 as